Screener
GeneDx Holdings WGS EPS (Diluted)
Discontinued — last reported Q1 '26
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by GeneDx Holdings in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: GeneDx Holdings’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001818331-26-000041
| Line item | Three months ended March 31, 2026 | 2025 |
|---|---|---|
| Numerator: | ||
| Net loss attributable to common stockholders | $(63,316) | $(6,529) |
| Denominator: | ||
| Basic and diluted weighted-average common shares outstanding | 29,335,126 | 28,147,948 |
| Basic and diluted loss per share | $(2.16) | $(0.23) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is GeneDx Holdings's EPS (diluted)?
- GeneDx Holdings (WGS) reported EPS (diluted) of -$2.16 in Q1 2026.
- How has GeneDx Holdings's EPS (diluted) changed year-over-year?
- GeneDx Holdings's EPS (diluted) decreased by 839.1% year-over-year, from -$0.23 to -$2.16.
- What is the long-term trend for GeneDx Holdings's EPS (diluted)?
- Over 2 years (2022 to 2025), GeneDx Holdings's EPS (diluted) has grown at a -88.3% compound annual growth rate (CAGR), from -$54.45 to -$0.75.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about GeneDx Holdings's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude